<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="a6e52787-dbcc-4bd0-8fa1-6875b3e80e2a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use SYFOVRE safely and effectively. See full prescribing information for SYFOVRE.<br/>
      <br/> SYFOVRE <sup>Â®</sup> (pegcetacoplan injection), for intravitreal use<br/> Initial U.S. Approval: 2021</title>
   <effectiveTime value="20250506"/>
   <setId root="b4434e61-9ec9-4e0e-bd60-45aaa0a87e64"/>
   <versionNumber value="10"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="961959629" root="1.3.6.1.4.1.519.1"/>
            <name>Apellis Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="691036974" root="1.3.6.1.4.1.519.1"/>
                        <name>Juzen Chemical Corporation</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="482220311" root="1.3.6.1.4.1.519.1"/>
                        <name>Bachem AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="069777290" root="1.3.6.1.4.1.519.1"/>
                        <name>Eurofins Lancaster Laboratories, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="849636258" root="1.3.6.1.4.1.519.1"/>
                        <name>Eurofins Advantar Laboratories, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="119461311" root="1.3.6.1.4.1.519.1"/>
                        <name>Micro Measurement Laboratories, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="118935952" root="1.3.6.1.4.1.519.1"/>
                        <name>West Services and Solutions LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="078525133" root="1.3.6.1.4.1.519.1"/>
                        <name>Packaging Coordinators, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="961754269" root="1.3.6.1.4.1.519.1"/>
                        <name>Lifecore Biomedical LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="080057170" root="1.3.6.1.4.1.519.1"/>
                        <name>Lifecore Biomedical</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="ac764b01-eec1-4af5-a4ea-67939885d9db"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241226"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73606-020" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Syfovre</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Pegcetacoplan</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="15" unit="mg"/>
                              <denominator value="0.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="TO3JYR3BOU" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Pegcetacoplan</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="TO3JYR3BOU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Pegcetacoplan</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="5.95" unit="mg"/>
                              <denominator value="0.1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7YIN7J07X4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Trehalose dihydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q40Q9N063P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ACETIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73606-020-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230217"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43209" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73606-020-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230217"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217171" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230217"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>Clear</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38280" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVITREAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="5f21889c-90c1-4cb5-a9e2-99b1b9bd3be6"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="80%" align="left" valign="bottom"/>
                           <col width="20%" align="right" valign="bottom"/>
                           <tbody>
                              <tr>
                                 <td>Contraindications, Hypersensitivity (<linkHtml href="#S4.3">4.3</linkHtml>)</td>
                                 <td>12/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="44490eff-81c9-49c9-9455-514a845cc6a9"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1	INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).</paragraph>
               </text>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>SYFOVRE is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). (<linkHtml href="#S1">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="a19504d8-ee02-44a6-aadc-9cb78f56b512"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2	DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days. (<linkHtml href="#S2.2">2.2</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="170a2303-cd59-47a0-8494-0e234adcd691"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	General Dosing Information</title>
                     <text>
                        <paragraph>SYFOVRE must be administered by a qualified physician.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="233e16d2-43b7-4232-a8ca-4a5f42280dd9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="a48706e1-d885-4720-9fb2-82a4d750f1b2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Preparation for Administration</title>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="30%" align="left" valign="top"/>
                           <col width="70%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM1"/>
                                 </td>
                                 <td>Store SYFOVRE in the refrigerator between 2Â°C to 8Â°C (36Â°F to 46Â°F); Keep the vial in the original carton to protect from light.</td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM2"/>
                                 </td>
                                 <td>Remove the carton from the refrigerator. Keep the vial in the original carton at room temperature 20Â°C to 25Â°C (68Â°F to 77Â°F), for at least 15 minutes prior to injection, but no longer than 8 hours. Fill the syringe immediately prior to the injection.</td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM3"/>
                                 </td>
                                 <td>
                                    <content styleCode="bold">Do not</content> shake the vial.<br/> The vial is for use in a single eye.</td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM4"/>
                                 </td>
                                 <td>Inspect the solution. It is a clear, colorless to light yellow  aqueous solution. <content styleCode="bold">Do not use if:</content>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>particulates, cloudiness, or discoloration are visible,</item>
                                       <item>the vial shows signs of damage or tampering,</item>
                                       <item>or if the expiration date has passed</item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%" styleCode="Noautorules">
                           <col width="20%" align="left" valign="top"/>
                           <col width="30%" align="left" valign="top"/>
                           <col width="30%" align="left" valign="top"/>
                           <col width="20%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">STEP 1</content>
                                    <br/> Gather the supplies needed:</td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <list listType="unordered" styleCode="DIsc">
                                       <item>One SYFOVRE vial (included)</item>
                                       <item>One sterile 5-micron filter needle (<content styleCode="bold">not included</content>)</item>
                                       <item>One sterile 1-mL Luer-lock syringe with a 0.1 mL dose mark (<content styleCode="bold">not included</content>)</item>
                                       <item>One sterile Â½ inch: 29-gauge thin-wall injection needle with Luer-lock hub or a 27-gauge needle with Luer-lock hub (<content styleCode="bold">not included</content>)<br/>
                                          <content styleCode="bold">Note:</content>  Increased injection forces and/or increased injection time could be experienced if a smaller diameter injection needle is used (e.g., 30-gauge)</item>
                                       <item>Alcohol swab (<content styleCode="bold">not included</content>)</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4">Use aseptic technique to carry out the following preparation steps:</td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">STEP 2</content>
                                    <br/> Remove the flip-off cap from the vial (see <linkHtml href="#FIGURE1a">Figure 1a</linkHtml>) and clean the vial septum with an alcohol swab and wait for the alcohol to dry out (see <linkHtml href="#FIGURE1b">Figure 1b</linkHtml>).</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph ID="FIGURE1a">Figure 1a:</paragraph>
                                 </td>
                                 <td/>
                                 <td>
                                    <paragraph ID="FIGURE1b">Figure 1b:</paragraph>
                                 </td>
                                 <td/>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <renderMultiMedia referencedObject="MM5"/>
                                 </td>
                                 <td/>
                                 <td>
                                    <renderMultiMedia referencedObject="MM6"/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">STEP 3</content>
                                    <br/>Attach the 5-micron filter needle onto a 1-mL Luer-lock syringe (see <linkHtml href="#FIGURE2">Figure 2</linkHtml>) by twisting it onto the Luer-lock syringe tip.</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph ID="FIGURE2">Figure 2:</paragraph>
                                 </td>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <renderMultiMedia referencedObject="MM7"/>
                                 </td>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">STEP 4</content>
                                    <br/> Push the filter needle into the center of the vial septum until the needle is submerged in the drug product to prevent withdrawal of air (see <linkHtml href="#FIGURE3a">Figure 3a</linkHtml>). To withdraw the entire contents of the vial into the syringe, hold the vial at a slightly inclined position. Withdraw the drug product slowly to prevent air bubbles. Continue to tilt the vial during withdrawal keeping the bevel of the filter needle submerged in the liquid until all of the fluid is withdrawn from the vial (see <linkHtml href="#FIGURE3b">Figure 3b</linkHtml>). <content styleCode="bold">*Do not</content> tap the syringe to remove air bubbles. While maintaining the filter needle within the vial, invert the syringe and move the plunger down and up until bubbles move to the top (see <linkHtml href="#FIGURE3c">Figure 3c</linkHtml>).</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph ID="FIGURE3a">Figure 3a:</paragraph>
                                 </td>
                                 <td/>
                                 <td>
                                    <paragraph ID="FIGURE3b">Figure 3b:</paragraph>
                                 </td>
                                 <td/>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <renderMultiMedia referencedObject="MM8"/>
                                 </td>
                                 <td/>
                                 <td>
                                    <renderMultiMedia referencedObject="MM9"/>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <paragraph ID="FIGURE3c">Figure 3c:</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td/>
                                 <td colspan="3">
                                    <paragraph>
                                       <renderMultiMedia referencedObject="MM10"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">STEP 5</content>
                                    <br/>Using aseptic technique, disconnect the filter needle from the syringe and dispose of it. <content styleCode="bold">Do not use the filter needle for injection.</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">STEP 6</content>
                                    <br/> Aseptically and firmly attach the injection needle onto the 1-mL Luer-lock syringe (see <linkHtml href="#FIGURE4">Figure 4</linkHtml>).</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph ID="FIGURE4">Figure 4:</paragraph>
                                 </td>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <renderMultiMedia referencedObject="MM11"/>
                                 </td>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td colspan="4">
                                    <content styleCode="bold">STEP 7</content>
                                    <br/>Check for air bubbles by holding the syringe with the needle pointing up. *<content styleCode="bold">Do not</content> tap the syringe to remove air bubbles.<br/> If there are any air bubbles, remove the needle cap and with the needle end facing up gently advance the plunger to the 0.1 mL dose mark (see <linkHtml href="#FIGURE5">Figure 5</linkHtml>). <br/>Only 0.1 mL (15 mg of SYFOVRE) should be administered to deliver a single dose. Any excess volume should be disposed.<br/>The syringe is ready for injection.</td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph ID="FIGURE5">Figure 5:</paragraph>
                                 </td>
                                 <td/>
                                 <td/>
                                 <td/>
                              </tr>
                              <tr>
                                 <td/>
                                 <td>
                                    <renderMultiMedia referencedObject="MM12"/>
                                 </td>
                                 <td/>
                                 <td/>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20241226"/>
                     <component>
                        <observationMedia ID="MM1">
                           <text>Figure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Figure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM4">
                           <text>Figure</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM5">
                           <text>Figure 1a</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM6">
                           <text>Figure 1b</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-06.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM7">
                           <text>Figure 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-07.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM8">
                           <text>Figure 3a</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-08.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM9">
                           <text>Figure 3b</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-09.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM10">
                           <text>Figure 3c</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-10.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM11">
                           <text>Figure 4</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-11.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM12">
                           <text>Figure 5</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="pegcetacoplan-12.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="77f629dd-4a49-4479-8cd1-a5f27ceb4760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4	Injection Procedure</title>
                     <text>
                        <paragraph>Only 0.1 mL (15 mg of SYFOVRE) should be administered to deliver a single dose. Any excess volume should be disposed. Ensure that the injection is given <content styleCode="bold">immediately</content> after the preparation of the dose.</paragraph>
                        <paragraph>Prior to the intravitreal injection, patients should be monitored for elevated intraocular pressure (IOP) using tonometry <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>. If necessary, ocular hypotensive medication can be given to lower the IOP. The intravitreal injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum topical microbicide to disinfect the periocular skin, eyelid, and ocular surface should be administered prior to the injection.</paragraph>
                        <paragraph>Inject slowly until the rubber stopper reaches the end of the syringe to deliver the volume of 0.1 mL. Confirm delivery of the full dose by checking that the rubber stopper has reached the end of the syringe barrel.</paragraph>
                        <paragraph>Immediately following the intravitreal injection, patients should be monitored for elevations in IOP. Additional evaluation may include checking for perfusion of the optic nerve head and tonometry.</paragraph>
                        <paragraph>Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g., eye pain, redness of the eye, photophobia, blurring of vision) without delay <content styleCode="italics">[see <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]</content>.</paragraph>
                        <paragraph>Each vial should only be used for the treatment of a single eye. If the fellow eye requires treatment, a new sterile, vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before SYFOVRE administration. Repeat same procedure steps as above.</paragraph>
                        <paragraph>Any unused medicinal product or waste material should be disposed of in accordance with local regulations.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="b27ecfa8-2ebf-4d60-a1ca-75546cab97c3"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3	DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 150 mg/mL, clear, colorless to light yellow aqueous solution in a single-dose vial for administration of a single 0.1 mL dose.</paragraph>
               </text>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 150 mg/mL in a single-dose vial. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="49776101-10ab-40bf-a45c-0ccb7cbdc273"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4	CONTRAINDICATIONS</title>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Ocular or Periocular Infections (<linkHtml href="#S4.1">4.1</linkHtml>)</item>
                           <item>Active Intraocular Inflammation (<linkHtml href="#S4.2">4.2</linkHtml>)</item>
                           <item>Hypersensitivity (<linkHtml href="#S4.3">4.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S4.1">
                     <id root="cf59778e-690e-4d6c-82ab-6e811bdd47e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1	Ocular or Periocular Infections</title>
                     <text>
                        <paragraph>SYFOVRE is contraindicated in patients with ocular or periocular infections <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.2">
                     <id root="6d9971b4-4445-47b3-9c73-953ba2d598ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2	Active Intraocular Inflammation</title>
                     <text>
                        <paragraph>SYFOVRE is contraindicated in patients with active intraocular inflammation.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S4.3">
                     <id root="5acf8e9d-3c2f-452b-8868-69ea455f252c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.3	Hypersensitivity</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">SYFOVRE is contraindicated in patients with hypersensitivity to pegcetacoplan or to any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred in patients treated with SYFOVRE <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="f36d4ea6-085b-4028-bb7c-1dde5b2205d7"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5	WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Endophthalmitis and Retinal Detachments (<linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>Retinal Vasculitis and/or Retinal Vascular Occlusion (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Neovascular AMD (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>Intraocular inflammation (<linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>Increased Intraocular Pressure (<linkHtml href="#S5.5">5.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="f042ddc2-b677-46e1-b6d7-d79062e726a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Endophthalmitis and Retinal Detachments</title>
                     <text>
                        <paragraph>Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Proper aseptic injection technique must always be used when administering SYFOVRE in order to minimize the risk of endophthalmitis <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content>. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="c77c7199-7a84-43ea-9b30-512b414d2552"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 	Retinal Vasculitis and/or Retinal Vascular Occlusion</title>
                     <text>
                        <paragraph>Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay. 								</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="51ccc848-9cea-4b1f-b69d-9c5e2f99f7be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Neovascular AMD</title>
                     <text>
                        <paragraph>In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="380d5fde-6997-463e-87bf-5f3c4c26a490"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4	Intraocular Inflammation</title>
                     <text>
                        <paragraph>In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves patients may resume treatment with SYFOVRE.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="a678e294-b546-410e-b06c-d46a23223bc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Increased Intraocular Pressure</title>
                     <text>
                        <paragraph>Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="9bc96b26-8ba0-47e2-93f2-79cae79e88fa"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6	ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Ocular and periocular infections <content styleCode="italics">[see <linkHtml href="#S4.1">Contraindications (4.1)</linkHtml>]</content>
                     </item>
                     <item>Active intraocular inflammation <content styleCode="italics">[see <linkHtml href="#S4.2">Contraindications (4.2)</linkHtml>]</content>
                     </item>
                     <item>Hypersensitivity <content styleCode="italics">[see <linkHtml href="#S4.3">Contraindications (4.3)</linkHtml>]</content>
                     </item>
                     <item>Endophthalmitis and retinal detachments <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Retinal Vasculitis and/or Retinal Vascular Occlusion <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Neovascular AMD <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Intraocular inflammation <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>Increased intraocular pressure <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241226"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence â¥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, and conjunctival hemorrhage. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Apellis Pharmaceuticals, Inc. at 1-833-866-3346 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="ba5d0085-225d-479c-a1c1-088827ae5de6"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph> A total of 839 patients with GA in two Phase 3 studies (OAKS and DERBY) were treated with intravitreal SYFOVRE, 15 mg (0.1 mL of 150 mg/mL solution). Four hundred nineteen (419) of these patients were treated in the affected eye monthly and 420 were treated in the affected eye every other month. Four hundred seventeen (417) patients were assigned to sham. </paragraph>
                        <paragraph>The most common adverse reactions (â¥5%) reported in patients receiving SYFOVRE were ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, and conjunctival hemorrhage.</paragraph>
                        <table width="90%" ID="TABLE1">
                           <caption>Table 1: Adverse Reactions in Study Eye Reported in â¥2% of Patients Treated with  SYFOVRE Through Month 24 in Studies OAKS and DERBY</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <col width="25%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Adverse Reactions</th>
                                 <th styleCode="Rrule">PM<br/> (N = 419)<br/> %</th>
                                 <th styleCode="Rrule">PEOM<br/> (N = 420)<br/> %</th>
                                 <th styleCode="Rrule">Sham Pooled<br/> (N = 417)<br/> %</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4" align="left">PM: SYFOVRE monthly; PEOM: SYFOVRE every other month</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Ocular discomfort<footnote ID="tb1ft1">The following reported terms were combined:<br/>
                                       <content styleCode="bold">Ocular discomfort</content> included: eye pain, eye irritation, foreign body sensation in eyes, ocular discomfort, abnormal sensation in eye<br/>
                                       <content styleCode="bold">Neovascular age-related macular degeneration</content> included: exudative age-related macular degeneration, choroidal neovascularization<br/>
                                       <content styleCode="bold">Punctate keratitis</content> included: punctate keratitis, keratitis<br/>
                                       <content styleCode="bold">Intraocular inflammation</content> included: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, anterior chamber flare</footnote>
                                 </td>
                                 <td styleCode="Rrule">13</td>
                                 <td styleCode="Rrule">10</td>
                                 <td styleCode="Rrule">11</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Neovascular age-related macular degeneration<footnoteRef IDREF="tb1ft1"/>
                                 </td>
                                 <td styleCode="Rrule">12</td>
                                 <td styleCode="Rrule">7</td>
                                 <td styleCode="Rrule">3</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Vitreous floaters</td>
                                 <td styleCode="Rrule">10</td>
                                 <td styleCode="Rrule">7</td>
                                 <td styleCode="Rrule">1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Conjunctival hemorrhage</td>
                                 <td styleCode="Rrule">8</td>
                                 <td styleCode="Rrule">8</td>
                                 <td styleCode="Rrule">4</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Vitreous detachment</td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">6</td>
                                 <td styleCode="Rrule">3</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Retinal hemorrhage</td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">5</td>
                                 <td styleCode="Rrule">3</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Punctate keratitis<footnoteRef IDREF="tb1ft1"/>
                                 </td>
                                 <td styleCode="Rrule">5</td>
                                 <td styleCode="Rrule">3</td>
                                 <td styleCode="Rrule">&lt;1</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Posterior capsule opacification</td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">3</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Â Â Intraocular inflammation<footnoteRef IDREF="tb1ft1"/>
                                 </td>
                                 <td styleCode="Rrule">4</td>
                                 <td styleCode="Rrule">2</td>
                                 <td styleCode="Rrule">&lt;1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Â Â Intraocular pressure increased</td>
                                 <td styleCode="Rrule">2</td>
                                 <td styleCode="Rrule">3</td>
                                 <td styleCode="Rrule">&lt;1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph> Endophthalmitis, retinal detachment, hyphema and retinal tears were reported in less than 1% of patients.</paragraph>
                        <paragraph>Optic ischemic neuropathy was reported in 1.7% of patients treated monthly, 0.2% of patients treated every other month and 0.0% of patients assigned to sham. Deaths were reported in 6.7% of patients treated monthly, 3.6% of patients treated every other month and 3.8% of patients assigned to sham. The rates and causes of death were consistent with the elderly study population.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="cd457065-4bdf-47cd-8062-07ce09a3e9a3"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of SYFOVRE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Eye disorders</content>: retinal vasculitis with or without retinal vascular occlusion.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Systemic reactions:</content> anaphylaxis, rash, and urticaria.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="1391a5a0-8e33-4da5-8c62-6d46449a56cc"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8	USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241226"/>
               <component>
                  <section ID="S8.1">
                     <id root="a6d95566-1981-4283-8f23-1fdb68cdcc8f"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1	Pregnancy</title>
                     <effectiveTime value="20241226"/>
                     <component>
                        <section>
                           <id root="f184e5f8-d71d-4440-b3fa-fbe19225508a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no adequate and well-controlled studies of SYFOVRE administration in pregnant women to inform a drug-associated risk. The use of SYFOVRE may be considered following an assessment of the risks and benefits.</paragraph>
                              <paragraph> Systemic exposure of SYFOVRE following ocular administration is low <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Subcutaneous administration of pegcetacoplan to pregnant monkeys from the mid gestation period through birth resulted in increased incidences of abortions and stillbirths at systemic exposures 1040-fold higher than that observed in humans at the maximum recommended human ophthalmic dose (MRHOD) of SYFOVRE (based on the area under the curve (AUC) systemically measured levels). No adverse maternal or fetal effects were observed in monkeys at systemic exposures approximately 470-fold higher than that observed in humans at the MRHOD <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="698df4d4-1594-4abb-8b25-bfec1ceba822"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                           <component>
                              <section ID="ANIMAL_DATA">
                                 <id root="0dcf7613-cce1-4a62-98b0-d9a7ed9ee335"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In embryofetal development studies, subcutaneous administration of pegcetacoplan to pregnant cynomolgus monkeys from the mid gestation period through birth produced increased incidences of abortions and stillbirths at doses of 28 mg/kg/day [approximately 1040-fold higher than the MRHOD based on exposure (AUC)]. Pegcetacoplan was not maternally toxic and did not produce adverse embryofetal effects in the monkey at subcutaneous doses of 7 mg/kg/day. (approximately 470-fold higher than the MRHOD). No developmental effects were observed in infants up to 6 months postpartum. Minimal systemic exposure to pegcetacoplan (less than 1%, not pharmacologically significant) was detected in fetuses from monkeys treated subcutaneously with 28 mg/kg/day from the period of organogenesis through the second trimester.</paragraph>
                                 </text>
                                 <effectiveTime value="20241226"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2a">
                     <id root="b79ecdab-ec72-42d8-a080-693d85baed0d"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241226"/>
                     <component>
                        <section>
                           <id root="d70c30db-b001-4a0d-b207-b41d4bcb7e6e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>It is not known whether intravitreal administered pegcetacoplan is secreted in human milk or whether there is potential for absorption and harm to the infant. Animal data suggest that the risk of clinically relevant exposure to the infant following maternal intravitreal treatment is minimal <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>. Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when SYFOVRE is administered to a nursing woman.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="c8682685-3930-467c-a7ea-a0f3c0bfd61d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                           <component>
                              <section ID="ANIMAL_DATA_2">
                                 <id root="05f3ed7d-4748-45cf-b82e-fca6ca20be77"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Pegcetacoplan was detectable in milk of lactating monkeys after subcutaneous administration at less than 1% concentration of serum levels but was not detectable in the serum of nursing infants.</paragraph>
                                 </text>
                                 <effectiveTime value="20241226"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3a">
                     <id root="4004d311-b4e6-4320-90d7-ff46e01ffb0e"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3	Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20241226"/>
                     <component>
                        <section>
                           <id root="beedeed6-968d-41ad-8f57-5123f9520704"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                           <component>
                              <section>
                                 <id root="76c4818c-47a3-496e-a993-f8275a3a7d80"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>It is recommended that women of childbearing potential use effective contraception methods to prevent pregnancy during treatment with intravitreal pegcetacoplan. Advise female patients of reproductive potential to use effective contraception during treatment with SYFOVRE and for 40 days after the last dose. For women planning to become pregnant, the use of SYFOVRE may be considered following an assessment of the risks and benefits.</paragraph>
                                 </text>
                                 <effectiveTime value="20241226"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="dbe393a8-8948-4e4d-924d-0ee79fe6edbb"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4	Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of SYFOVRE in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="e0a0fbd5-73c1-48e7-a901-455527a82292"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5	Geriatric Use</title>
                     <text>
                        <paragraph>In clinical studies, approximately 97% (813/839) of patients randomized to treatment with SYFOVRE were â¥ 65 years of age and approximately 72% (607/839) were â¥ 75 years of age. No significant differences in efficacy or safety were seen with increasing age in these studies. No dosage regimen adjustment is recommended based on age.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="7e5d4c05-40c5-4d3f-b575-efcec4f70a6c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11	DESCRIPTION</title>
               <text>
                  <paragraph>SYFOVRE contains pegcetacoplan, a complement inhibitor. Pegcetacoplan is a symmetrical molecule composed of two identical pentadecapeptides covalently bound to the ends of a linear 40 kiloDalton (kDa) polyethylene glycol (PEG) molecule. The peptide portions of pegcetacoplan contain 1-methyl-L-tryptophan (Trp(Me)) in position 4 and amino (ethoxyethoxy) acetic acid (AEEA) in position 14.</paragraph>
                  <paragraph>The molecular weight of pegcetacoplan is approximately 43.5 kDa. The molecular formula is C<sub>1970</sub>H<sub>3848</sub>N<sub>50</sub>O<sub>947</sub>S<sub>4</sub>. The structure of pegcetacoplan is shown below.</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM13"/>
                  </paragraph>
                  <paragraph>SYFOVRE (pegcetacoplan injection) is a sterile, clear, colorless to light yellow aqueous solution in a single-dose vial for intravitreal use. Each vial allows for the delivery of 0.1 mL of solution containing 15 mg pegcetacoplan, trehalose dihydrate (5.95 mg), glacial acetic acid (0.0895 mg), sodium acetate trihydrate (0.0353 mg), and Water for Injection. SYFOVRE may also contain sodium hydroxide and/or additional glacial acetic acid for adjustment to a target pH of 5.0. SYFOVRE does not contain an anti-microbial preservative.</paragraph>
               </text>
               <effectiveTime value="20241226"/>
               <component>
                  <observationMedia ID="MM13">
                     <text>Chemical Formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pegcetacoplan-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="d76a6b97-308d-41a7-a36f-4eb0ed9e58ae"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12	CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241226"/>
               <component>
                  <section ID="S12.1">
                     <id root="dd1498c0-de0b-4e9d-b896-861518188a6f"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1	Mechanism of Action</title>
                     <text>
                        <paragraph>Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="3c65a0bb-d0d3-4ef9-bff4-e3b024d9666e"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2	Pharmacodynamics</title>
                     <effectiveTime value="20241226"/>
                     <component>
                        <section>
                           <id root="a33cd55e-0de9-4877-81e2-5d5dffcbd67c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>Subcutaneous (SC) dosing of pegcetacoplan did not result in QT prolongation. Systemic exposures following intravitreal (IVT) administration are much lower than with SC administration, therefore QT prolongation following IVT pegcetacoplan is not expected.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="211c9d82-ad2c-4495-85cb-c698db4fb8eb"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3	Pharmacokinetics</title>
                     <text>
                        <paragraph>SYFOVRE is administered directly into the vitreous to exert local effects in the eye.</paragraph>
                        <paragraph>Following repeat intravitreal administration of pegcetacoplan at a dose of 15 mg, geometric mean (%CV) serum C<sub>max</sub> value at steady state was 2.2 Î¼g/mL (28.7%) and 1.5 Î¼g/mL (58.1%) for GA patients dosed monthly and every other month, respectively. The steady state geometric mean (%CV) serum trough concentrations were 1.0  Î¼g/mL (52.3%) and 0.2 Î¼g/mL (89.6%) for patients treated monthly and every other month, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                     <component>
                        <section>
                           <id root="6d1e162e-d551-4d40-beb8-65da12fd9830"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following intravitreal administration of pegcetacoplan, the systemic median T<sub>max</sub> of pegcetacoplan is between 7 and 14 days. Following intravitreal treatment, systemic exposure of pegcetacoplan increases approximately proportionally over a dosage range from 4 to 20 mg.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="91d84f5a-e615-4812-8b46-7db42c2a7f76"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>The geometric mean (95%CI) volume of distribution of pegcetacoplan is approximately 1.85 L (1.62 - 2.12) in patients with GA following intravitreal administration.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="02dc1070-b07b-4d18-b712-9fe58df710cf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The estimated geometric mean (%CV) of clearance (CL) is 0.284 L/day (21.1%) and geometric mean half-life of elimination (t<sub>1/2</sub>) is 4.5 days (21.1%) in patients with GA.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                           <component>
                              <section>
                                 <id root="ee732c19-6041-4cfd-aa86-8a5c7824edde"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Pegcetacoplan is expected to be metabolized into small peptides and amino acids by catabolic pathways.</paragraph>
                                 </text>
                                 <effectiveTime value="20241226"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="16c28b81-b83f-475f-bcde-0b3fedc6178f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>There were no clinically significant differences on the pharmacokinetics of pegcetacoplan intravitreal administration based on age (60 to 97 years old), gender, renal impairment, and hepatic function as evaluated by total bilirubin (0.05-1.7 mg/dL), albumin (2.96-5.38 g/dL), aspartate aminotransferase (8.7-101 IU/L), or alanine aminotransferase (5.9-136 IU/L).</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.6">
                     <id root="6efcf34d-caa7-43e4-87ed-2323629d8725"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6	Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Difference in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies.</paragraph>
                        <paragraph>In the 24-month period in studies OAKS and DERBY, the incidence of anti-pegcetacoplan peptide antibodies in patients treated with pegcetacoplan was 4% (18/415 evaluable patients) and 2.5% (10/404 evaluable patients), respectively. Because of the low incidence of anti-pegcetacoplan peptide antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of pegcetacoplan is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="586efa8b-901c-4e12-bb27-575234196be3"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13	NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241226"/>
               <component>
                  <section ID="S13.1">
                     <id root="f963be9c-1c66-4907-9712-f4e6048da3f2"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20241226"/>
                     <component>
                        <section>
                           <id root="5a3522b7-3963-4e30-85c4-0b83d8c62632"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Animal carcinogenicity studies of pegcetacoplan have not been conducted.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3f4bee78-1bc7-4efe-ab36-02446c5c0d54"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Pegcetacoplan was not mutagenic when tested in in vitro bacterial reverse mutation (Ames) assays and was not genotoxic in an in vitro assay in human TK6 cells or in an in vivo micronucleus assay in mice.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="82a2b8ac-a44b-484c-b726-2cb108b98070"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>There are no fertility data in humans or animals. There were no microscopic abnormalities in male or female reproductive organs in toxicity studies in rabbits and monkeys indicative of an impact of pegcetacoplan on fertility.</paragraph>
                           </text>
                           <effectiveTime value="20241226"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="1cb75908-5799-4bf8-b76a-64f7d3af716a"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14	CLINICAL STUDIES</title>
               <text>
                  <paragraph>The safety and efficacy of SYFOVRE were assessed in two multi-center, randomized, sham-controlled studies in patients with GA (atrophic nonexudative age-related macular degeneration), with or without subfoveal involvement, secondary to AMD in a total of 1258 randomized patients (SYFOVRE 839 patients, sham 419 patients). Studies OAKS (APL2-304; NCT03525613) and DERBY (APL2-303; NCT03525600) were 24 months in duration, in which patients received treatment for the entire length of the study.</paragraph>
                  <paragraph>Patient ages ranged from 60 to 100 years with a mean of 78.7 years. Mean (standard deviation) total area of GA lesions(s) at baseline in the study eye (in mm<sup>2</sup>) were 8.23 (3.83) and 8.29 (4.11) for OAKS and DERBY respectively.</paragraph>
                  <paragraph>In each study, patients were randomly assigned in a 2:2:1:1 ratio to 1 of 4 dosing regimens:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>1) SYFOVRE administered at 15 mg/0.1 mL monthly;</item>
                     <item>2) SYFOVRE administered at 15 mg/0.1 mL every other month;</item>
                     <item>3) sham administered monthly;</item>
                     <item>4) sham administered every other month.</item>
                  </list>
                  <paragraph>In OAKS, 31% of patients in the monthly group, 21% of patients in the every other month and 25% of the patients assigned to sham discontinued treatment prior to Month 24. In DERBY, 29% of patients in the monthly group, 22% of patients in the every other month and 21% of the patients assigned to sham discontinued treatment prior to Month 24.</paragraph>
                  <paragraph>There was a reduction in the mean rate of GA lesion growth observed in both studies. </paragraph>
                  <paragraph>Detailed results are shown in Table 2 and Figures 1 and 2.</paragraph>
                  <table width="90%" ID="TABLE2">
                     <caption>Table 2: Analysis of Change from Baseline in Study Eye GA Lesion Area Measured by FAF in Studies OAKS and DERBY</caption>
                     <col width="16%" align="left" valign="middle"/>
                     <col width="21%" align="center" valign="middle"/>
                     <col width="21%" align="center" valign="middle"/>
                     <col width="21%" align="center" valign="middle"/>
                     <col width="21%" align="center" valign="middle"/>
                     <thead>
                        <tr styleCode="Botrule">
                           <th styleCode="Lrule Rrule" rowspan="2" align="center">Time Period</th>
                           <th styleCode="Rrule" rowspan="2" align="center">Group</th>
                           <th styleCode="Rrule" colspan="3">Rate of GA Lesion Area Growth (mm<sup>2</sup>) <footnote ID="foot2a">Based on a mixed effects model for repeated measures assuming a piecewise linear trend in time with knots at Month 6, Month 12, and Month 18. The model included effects for treatment,â¯baseline GA lesion area (&lt;7.5â¯mm<sup>2</sup> or â¥7.5â¯mm<sup>2</sup>), time terms,â¯presence of  choroidal neovascularization in the fellow eye (yes or no), time terms by treatment interactions, and time terms by baseline GA lesion area (&lt;7.5â¯mm<sup>2</sup> or â¥7.5â¯mm<sup>2</sup>) interactions. Time terms include a linear effect of time for each 6-month time period.</footnote>
                           </th>
                        </tr>
                        <tr>
                           <th styleCode="Rrule" align="center">Slope (SE)</th>
                           <th styleCode="Rrule">Difference (95% CI) in Slope from Sham Pooled 									</th>
                           <th styleCode="Rrule">Percent Difference from Sham Pooled</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td colspan="5" align="left">GA: Geographic atrophy; FAF: fundus autofluorescence; PM: SYFOVRE monthly; PEOM: SYFOVRE every other month; SE: standard error; CI: confidence interval</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">OAKS (PM: N=202; PEOM: N=205; Sham Pooled: N=207)</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Baseline to Month 24<footnote ID="foot2b">Slope for baseline to Month 24 is an average of slope of baseline to Month 6, Month 6 to Month 12, Month 12 to Month 18, and Month 18 to Month 24.</footnote>
                              </content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">3.11 (0.148)</td>
                           <td styleCode="Rrule">â0.87<br/>(â1.27 to â0.47)</td>
                           <td styleCode="Rrule">â21.9%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">3.26 (0.134)</td>
                           <td styleCode="Rrule">â0.72<br/>(â1.10 to â0.33)</td>
                           <td styleCode="Rrule">â18.1%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">3.98 (0.143)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Baseline to Month 6</content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">0.76 (0.046)</td>
                           <td styleCode="Rrule">â0.22<br/>(â0.35 to â0.09)</td>
                           <td styleCode="Rrule">â22.7%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">0.82 (0.043)</td>
                           <td styleCode="Rrule">â0.16<br/>(â0.29 to â0.04)</td>
                           <td styleCode="Rrule">â16.4%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">0.98 (0.047)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Month 6 to Month 12</content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">0.78 (0.060)</td>
                           <td styleCode="Rrule">â0.19<br/>(â0.34 to â0.03)</td>
                           <td styleCode="Rrule">â19.2%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">0.82 (0.057)</td>
                           <td styleCode="Rrule">â0.15<br/>(â0.30 to â0.00)</td>
                           <td styleCode="Rrule">â15.7%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">0.97 (0.052)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Month 12 to Month 18</content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">0.80 (0.050)</td>
                           <td styleCode="Rrule">â0.23<br/>(â0.37 to â0.08)</td>
                           <td styleCode="Rrule">â22.1%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">0.87 (0.050)</td>
                           <td styleCode="Rrule">â0.16<br/>(â0.30 to â0.02)</td>
                           <td styleCode="Rrule">â15.4%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">1.03 (0.053)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Month 18 to Month 24</content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">0.76 (0.067)</td>
                           <td styleCode="Rrule">â0.23<br/>(â0.41 to â0.06)</td>
                           <td styleCode="Rrule">â23.5%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">0.75 (0.044)</td>
                           <td styleCode="Rrule">â0.25<br/>(â0.39 to â0.10)</td>
                           <td styleCode="Rrule">â24.7%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">1.00 (0.058)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="5">
                              <content styleCode="bold">DERBY (PM: N=201; PEOM: N=201; Sham Pooled: N=195)</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Baseline to Month 24<footnoteRef IDREF="foot2b"/>
                              </content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">3.28 (0.125)</td>
                           <td styleCode="Rrule">â0.73<br/>(â1.14 to â0.31)</td>
                           <td styleCode="Rrule">â18.1%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">3.31 (0.129)</td>
                           <td styleCode="Rrule">â0.70<br/>(â1.11 to â0.28)</td>
                           <td styleCode="Rrule">â17.4%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">4.00 (0.169)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Baseline to Month 6</content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">0.91 (0.048)</td>
                           <td styleCode="Rrule">â0.05<br/>(â0.19 to 0.08)</td>
                           <td styleCode="Rrule">â5.7%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">0.88 (0.047)</td>
                           <td styleCode="Rrule">â0.08<br/>(â0.21 to 0.05)</td>
                           <td styleCode="Rrule">â8.2%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">0.96 (0.050)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Month 6 to Month 12</content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">0.84 (0.051)</td>
                           <td styleCode="Rrule">â0.17<br/>(â0.33 to â0.02)</td>
                           <td styleCode="Rrule">â17.0%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">0.85 (0.051)</td>
                           <td styleCode="Rrule">â0.17<br/>(â0.32 to â0.01)</td>
                           <td styleCode="Rrule">â16.4%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">1.01 (0.060)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Month 12 to Month 18</content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">0.90 (0.049)</td>
                           <td styleCode="Rrule">â0.14<br/>(â0.29 to 0.00)</td>
                           <td styleCode="Rrule">â13.8%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">0.88 (0.051)</td>
                           <td styleCode="Rrule">â0.17<br/>(â0.32 to â0.02)</td>
                           <td styleCode="Rrule">â16.0%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">1.05 (0.056)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" rowspan="3">
                              <content styleCode="bold">Month 18 to Month 24</content>
                           </td>
                           <td styleCode="Rrule">
                              <content styleCode="bold">PM</content>
                           </td>
                           <td styleCode="Rrule">0.63 (0.068)</td>
                           <td styleCode="Rrule">â0.35<br/>(â0.52 to â0.18)</td>
                           <td styleCode="Rrule">â36.1%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">PEOM</content>
                           </td>
                           <td styleCode="Rrule">0.69 (0.053)</td>
                           <td styleCode="Rrule">â0.28<br/>(â0.43 to â0.14)</td>
                           <td styleCode="Rrule">â29.1%</td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule" align="center">
                              <content styleCode="bold">Sham Pooled</content>
                           </td>
                           <td styleCode="Rrule">0.98 (0.055)</td>
                           <td styleCode="Rrule" colspan="2">NA</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Mean Rate of Change from Baseline in Study Eye GA Lesion Area Measured by FAF in OAKS</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM14"/>
                  </paragraph>
                  <paragraph>GA: Geographic atrophy; FAF: fundus autofluorescence; PM: SYFOVRE monthly; PEOM: SYFOVRE every other month; SE: standard error.<br/>Based on a mixed effects model for repeated measures assuming a piecewise linear trend in time with knots at Month 6, Month 12, and Month 18. The model included effects for treatment,â¯baseline GA lesion area (&lt;7.5â¯mm<sup>2</sup> or â¥7.5â¯mm<sup>2</sup>), time terms,â¯presence of choroidal neovascularization in the fellow eye (yes or no), time terms by treatment interactions, and time terms by baseline GA lesion area (&lt;7.5â¯mm<sup>2</sup> or â¥7.5â¯mm<sup>2</sup>) interactions. Time terms include a linear effect of time for each 6-month time period.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2: Mean Rate of Change from Baseline in Study Eye GA Lesion Area Measured by FAF in DERBY</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM15"/>
                  </paragraph>
                  <paragraph>GA: Geographic atrophy; FAF: fundus autofluorescence; PM: SYFOVRE monthly; PEOM: SYFOVRE every other month; SE: standard error.<br/>Based on a mixed effects model for repeated measures assuming a piecewise linear trend in time with knots at Month 6, Month 12, and Month 18. The model included effects for treatment,â¯baseline GA lesion area (&lt;7.5â¯mm<sup>2</sup> or â¥7.5â¯mm<sup>2</sup>), time terms,â¯presence of choroidal neovascularization in the fellow eye (yes or no), time terms by treatment interactions, and time terms by baseline GA lesion area (&lt;7.5â¯mm<sup>2</sup> or â¥7.5â¯mm<sup>2</sup>) interactions. Time terms include a linear effect of time for each 6-month time period.</paragraph>
               </text>
               <effectiveTime value="20241226"/>
               <component>
                  <observationMedia ID="MM14">
                     <text>Figure 1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pegcetacoplan-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM15">
                     <text>Figure 2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pegcetacoplan-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="cb9532fd-52cf-4a68-a5bc-7b282eb99c94"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16	HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20241226"/>
               <component>
                  <section ID="S16.1">
                     <id root="d9cf4696-7999-4cc5-bbdd-3e438328c1e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1	How Supplied</title>
                     <text>
                        <paragraph>SYFOVRE (pegcetacoplan injection) is supplied as a clear, colorless to light yellow aqueous solution. Each SYFOVRE carton (NDC 73606-020-01) contains one single-dose glass vial. Each glass vial contains an overfill amount to allow for administration of a single 0.1 mL dose of solution containing 15 mg of SYFOVRE.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="8f0111ce-9be3-48cd-9b10-3ec8b8d119e9"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2	Storage and Handling</title>
                     <text>
                        <paragraph>Refrigerate SYFOVRE between 2Â°C to 8Â°C (36Â°F to 46Â°F). Store the vial in the original carton to protect from light.</paragraph>
                        <paragraph>Do not use beyond the expiration date on the carton.</paragraph>
                        <paragraph>Do not shake.</paragraph>
                     </text>
                     <effectiveTime value="20241226"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="ef453294-69f2-4b41-9103-2af279b4a71d"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17	PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise patients that following SYFOVRE administration, patients are at risk of developing endophthalmitis, retinal detachments, retinal vasculitis with or without retinal vascular occlusion and neovascular AMD. If the eye becomes red, sensitive to light, painful, or if a patient develops any change in vision such as flashing lights, blurred vision or metamorphopsia, instruct the patient to seek immediate care from an ophthalmologist <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>, <linkHtml href="#S5.3">5.3)</linkHtml>]</content>.</paragraph>
                  <paragraph>Patients may experience temporary visual disturbances associated either with the intravitreal injection with SYFOVRE or the eye examination <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. Advise patients not to drive or use machinery until visual function has recovered sufficiently.</paragraph>
               </text>
               <effectiveTime value="20241226"/>
            </section>
         </component>
         <component>
            <section>
               <id root="a753ea54-b262-4fe5-9e67-e3ed4e94d340"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for:<br/>Apellis Pharmaceuticals, Inc.<br/>100 Fifth Avenue<br/>Waltham, MA 02451</paragraph>
                  <paragraph>For patent information: www.apellis.com/productpatent</paragraph>
                  <paragraph>Copyright Â© 2024 Apellis Pharmaceuticals, Inc. All rights reserved.<br/> SYFOVRE is a registered trademark of Apellis Pharmaceuticals, Inc.</paragraph>
                  <paragraph>SYF-PI-20Dec2024-3.0</paragraph>
               </text>
               <effectiveTime value="20241226"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ff5d5740-352c-4fd9-9f51-1bd7c69fdd3d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 15 mg Vial Carton</title>
               <text>
                  <paragraph>Apellis</paragraph>
                  <paragraph>NDC 73606-020-01</paragraph>
                  <paragraph>SYFOVRE<sub>Â®</sub>
                     <br/> (pegcetacoplan injection)</paragraph>
                  <paragraph>15 mg (0.1 mL of 150 mg/mL solution)</paragraph>
                  <paragraph>One single-dose vial. Discard unused portion.</paragraph>
                  <paragraph>For Intravitreal Use.</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <renderMultiMedia referencedObject="MM16"/>
               </text>
               <effectiveTime value="20241226"/>
               <component>
                  <observationMedia ID="MM16">
                     <text>PRINCIPAL DISPLAY PANEL - 15 mg Vial Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="pegcetacoplan-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>